

Attaphol Pawarode

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/633454/publications.pdf>

Version: 2024-02-01

71
papers

2,079
citations

279701

23
h-index

243529

44
g-index

74
all docs

74
docs citations

74
times ranked

3564
citing authors

#	ARTICLE	IF	CITATIONS
1	Is age a risk factor for cognitive changes following hematopoietic cell transplantation?. Bone Marrow Transplantation, 2021, 56, 567-569.	1.3	0
2	Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Advances, 2021, 5, 5047-5056.	2.5	10
3	Pneumocystis Jirovecii Infection in Autologous Hematopoietic Stem Cell Transplant Recipients. Blood, 2021, 138, 4898-4898.	0.6	1
4	The utility of cognitive changes in identifying those with acute graft vs. host disease following allogeneic hematopoietic cell transplant. Clinical Neuropsychologist, 2020, 34, 969-980.	1.5	0
5	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	2.5	18
6	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
7	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	2.5	63
8	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica, 2020, 105, 1329-1338.	1.7	23
9	Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to Reduce Acute Gvhd: Study Design on a Randomized Double Blind Placebo Controlled Phase III Clinical Trial (CATHY Study). Biology of Blood and Marrow Transplantation, 2020, 26, S180-S181.	2.0	4
10	Mitigating Damage Response with CD24 Fusion Protein for Prevention of Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, S52-S53.	2.0	5
11	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	3.3	27
12	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	3.2	10
13	A Phase I/II Clinical Trial of Type 1 Interferon for Reduction of Relapse after HCT in High Risk AML. Biology of Blood and Marrow Transplantation, 2019, 25, S12-S13.	2.0	2
14	The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD). Biology of Blood and Marrow Transplantation, 2019, 25, S26-S27.	2.0	4
15	Ultrasensitive Genomic Minimal Residual Disease Detection in Peripheral Blood after Allogeneic HSCT for MDS Is Associated with Increased Relapse Risk and Inferior Survival. Biology of Blood and Marrow Transplantation, 2019, 25, S127-S128.	2.0	0
16	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 1492-1497.	2.0	23
17	Comparison of Gvhd Biomarker Algorithms for Predicting Lethal Gvhd and Non-Relapse Mortality. Biology of Blood and Marrow Transplantation, 2019, 25, S53-S54.	2.0	3
18	Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1682-1688.	2.0	5

#	ARTICLE	IF	CITATIONS
19	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	2.5	12
20	Correlation of Radiographic Abnormalities on Computer Tomography (CT) with Broncho-Alveolar Lavage (BAL) Results. What are Our Radiologists Reading?. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S97-S98.	2.0	1
21	Î±1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018, 131, 1372-1379.	0.6	81
22	Impact of Broncho-Alveolar Lavage on the Diagnosis and Management of Pulmonary Complications Following Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S98.	2.0	1
23	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	0.6	140
24	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
25	Allogeneic haematopoietic cell transplantation for extranodal natural killer/Tâ€cell lymphoma, nasal type: a <scp>CIBMTR</scp> analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	1.2	59
26	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	2.5	35
27	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. <i>Cancer</i> , 2017, 123, 3141-3149.	2.0	65
28	Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 522-528.	2.0	49
29	Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. <i>Blood</i> , 2017, 130, 1760-1767.	0.6	57
30	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	0.6	210
31	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	2.3	166
32	Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
33	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
34	Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 862-868.	2.0	40
35	Quantitative Analysis of MR Imaging to Assess Treatment Response for Patients with Multiple Myeloma by Using Dynamic Intensity Entropy Transformation: A Preliminary Study. <i>Radiology</i> , 2016, 278, 449-457.	3.6	7
36	Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 54-60.	2.0	12

#	ARTICLE	IF	CITATIONS
37	FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. <i>Bone Marrow Transplantation</i> , 2016, 51, 511-520.	1.3	40
38	An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 509-509.	0.6	1
39	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. <i>Blood</i> , 2016, 128, 510-510.	0.6	0
40	The Graft-Versus-Lymphoma Effect in Diffuse Large B-Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S204-S205.	2.0	0
41	Phase II Clinical Trial of Etanercept Plus Extracorporeal Photopheresis GVHD Prophylaxis Following Unrelated Donor Reduced Intensity Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S337.	2.0	0
42	Predictive Value of Bronchiolitis Obliterans Syndrome Stage Op in Chronic Graft-versus-Host Disease of the Lung. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1127-1131.	2.0	43
43	Subcutaneous Panniculitis-Like T-Cell Lymphoma With Bone Marrow Involvement. <i>American Journal of Clinical Pathology</i> , 2015, 143, 265-273.	0.4	14
44	Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. <i>Annals of Hematology</i> , 2015, 94, 1033-1041.	0.8	9
45	Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies. <i>Blood</i> , 2015, 126, 1907-1907.	0.6	1
46	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 87-95.	5.1	113
47	Routine Prophylaxis of <i>Pneumocystis Jirovecii</i> Pneumonia in Recipients of Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S116-S117.	2.0	3
48	Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1426-1434.	2.0	20
49	Prognostic Value of TGF β ² at Diagnosis of Chronic GvHD. <i>Blood</i> , 2014, 124, 5875-5875.	0.6	0
50	A Combination of Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation From Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S138-S139.	2.0	0
51	Phase 2 Study of Allogeneic Hematopoietic Cell Transplant (HCT) Following Intermediate-Intensity Fludarabine and Busulfan x 4 (FluBu4) Conditioning for High-Risk or Advanced Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S238.	2.0	0
52	Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. <i>Haematologica</i> , 2013, 98, 179-184.	1.7	84
53	Application Of BOS 0-Potential Criteria As a Predictor For Bronchiolitis Obliterans Syndrome In Allogeneic Stem Cell Transplant Patients. <i>Blood</i> , 2013, 122, 2060-2060.	0.6	0
54	TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1525-1532.	2.0	50

#	ARTICLE	IF	CITATIONS
55	Targeting Histone Deacetylases As a New Strategy for Graft Versus Host Disease Prevention. <i>Blood</i> , 2012, 120, 740-740.	0.6	5
56	Unrelated Donor Transplants for Older AML Patients Using a Low Dose TBI Containing Regimen Are As Efficacious As Related Donor Transplants, and Exhibit Favorable Outcomes for Intermediate Risk Disease.. <i>Blood</i> , 2012, 120, 3119-3119.	0.6	0
57	An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future Graft-Versus-Host Disease Following Related Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 463-463.	0.6	1
58	Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 338-341.	0.6	12
59	Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan X 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML. <i>Blood</i> , 2010, 116, 35-35.	0.6	16
60	Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease. <i>Blood</i> , 2010, 116, 675-675.	0.6	6
61	Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.. <i>Blood</i> , 2009, 114, 43-43.	0.6	0
62	T/B and not T/B: High frequency of B-cell dyscrasias in T-LGL leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 845-846.	0.6	2
63	Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.. <i>Blood</i> , 2008, 112, 2150-2150.	0.6	3
64	Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants.. <i>Blood</i> , 2008, 112, 2163-2163.	0.6	3
65	Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. <i>Leukemia Research</i> , 2007, 31, 1589-1592.	0.4	15
66	Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 179-188.	1.1	75
67	Long-Term Outcome of Cyclosporin A Therapy for T-Cell Large Granular Lymphocyte Leukemia.. <i>Blood</i> , 2007, 110, 2063-2063.	0.6	0
68	Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2006, 167, 155-160.	1.0	13
69	The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.. <i>Blood</i> , 2005, 106, 1512-1512.	0.6	1
70	Outcomes of primary hepatocellular carcinoma treatment: An 8-year experience with 368 patients in Thailand. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 860-864.	1.4	35
71	Natural History of Untreated Primary Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 386-391.	0.6	146